Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

Vaccine

Volumn 27, Issue 49, 2009, Pages 6862-6868

  Esen, Meral ^a   Kremsner, Peter G ^a   Schleucher, Regina ^a   Gässler, Michael ^a   Imoukhuede, Egeruan Babatunde ^c   Imbault, Nathalie ^c   Leroy, Odile ^c   Jepsen, Søren ^c   Knudsen, Birgitte Walther ^c   Schumm, Michael ^b   Knobloch, Jürgen ^a   Theisen, Michael ^c   Mordmüller, Benjamin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

B cell ELISPOT; Malaria vaccine candidate; Phase I clinical trial

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; ANTIGEN; GMZ2 MALARIA VACCINE; MALARIA VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; ASEXUAL SPORE; BLOOD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GERMANY; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALAISE; MALARIA; MALE; MEMORY CELL; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; SKIN MANIFESTATION; SWELLING; TREATMENT DURATION; VOMITING;

ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 70350786394     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.011     Document Type: Article

References (28)

1. Sotiriades. Attempts at serotherapy in malaria. Greek Med 19 (1917) 27-28
2. Russel P.F., and Mohan B.N. The immunization of fowls against mosquito-borne Plasmodium gallinaceum by injections of serum and of inactivated homologous sporozoites. J Exp Med 76 (1942) 477-495
3. Cohen S., McGregor I.A., and Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 192 (1961) 733-737
4. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 3 (1991) 297-308
5. Singh S., Soe S., Mejia J., Roussilhon C., Theisen M., Corradin G., et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 5 (2004) 1010-1018
6. Huber W., Felger I., Matile H., Lipps H.J., Steiger S., and Beck H.P. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 2 (1997) 231-234
7. McColl D.J., and Anders R.F. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 1 (1997) 21-31
8. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., Bottius E., Kaidoh T., Aikawa M., et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 5 (1994) 1594-1602
9. Soe S., Theisen M., Roussilhon C., Aye K., and Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 1 (2004) 247-252
10. Meraldi V., Nebié I., Tiono A.B., Diallo D., Sanogo E., Theisen M., et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 6-7 (2004) 265-272
11. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 2 (1995) 409-418
12. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., and Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 6 (1990) 1633-1641
13. Khusmith S., and Druilhe P. Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes. Parasite Immunol 4 (1983) 357-368
14. Lunel F., and Druilhe P. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun 7 (1989) 2043-2049
15. Nebie I., Diarra A., Ouedraogo A., Soulama I., Bougouma E.C., Tiono A.B., et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 2 (2008) 759-766
16. Theisen M., Soe S., Brunstedt K., Follmann F., Bredmose L., Israelsen H., et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 9-10 (2004) 1188-1198
17. Carvalho L.J.M., Alves F.A., Bianco C., Oliveira S.G., Zanini G.M., Soe S., et al. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 2 (2005) 242-248
18. Oeuvray C., Theisen M., Rogier C., Trape J.F., Jepsen S., and Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 5 (2000) 2617-2620
19. Hermsen C.C., Verhage D.F., Telgt D.S.C., Teelen K., Bousema J.T., Roestenberg M., et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 15 (2007) 2930-2940
20. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 5601 (2002) 2199-2202
21. Hauser A.E., Debes G.F., Arce S., Cassese G., Hamann A., Radbruch A., et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 3 (2002) 1277-1282
22. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 6 (2002) 715-728
23. Baylor N.W., Egan W., and Richman P. Aluminum salts in vaccines-US perspective. Vaccine 20 Suppl 3 (2002) S18-S23
24. Yam K.K., Pouliot P., N'diaye M.M., Fournier S., Olivier M., and Cousineau B. Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 22 (2008) 2689-2699
25. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 12 (2005) 8017-8026
26. Wildling E., Winkler S., Kremsner P.G., Brandts C., Jenne L., and Wernsdorfer W.H. Malaria epidemiology in the province of Moyen Ogoov, Gabon. Trop Med Parasitol 2 (1995) 77-82
27. Sylla E.H., Kun J.F., and Kremsner P.G. Mosquito distribution and entomological inoculation rates in three malaria-endemic areas in Gabon. Trans R Soc Trop Med Hyg 6 (2000) 652-656
28. Amanna I.J., Carlson N.E., and Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 19 (2007) 1903-1915